CDKN2B and acute lymphoblastic leukemia: In pediatric B‐ALL, the AIEOP‐BFM group defined IKZF1plus as IKZF1 deletions combined with CDKN2A, CDKN2B, PAX5, or PAR1 deletions without an ERG deletion, which confers the worst outcomes.8